Kodama nets $7m to scale physical AI for ‘intelligent forestry’
Kodama—a California-based startup building physical AI for forestry—has raised a $7 million seed round to accelerate its…
Cosmax and Harvard Med eye weight-loss market as beauty and pharma blur
Cosmax is using its microbiome research to enter the wellness and pharmaceutical markets through a partnership with Harvard Medical School researchers. The Korean beauty manufacturer’s push beyond cosmetics into biotech and medicine comes as demand for weight-loss drugs and clinical anti-aging rises.
Ambrose expands rare disease pipeline with €161M AM-Pharma acquisition
The acquisition gives AM-Pharma’s ilofotase alfa another chance after setbacks in kidney disease. It also illustrates Ambrose’s strategy: acquire stalled compounds with existing human data and develop them for rare diseases, aiming to reduce the time and cost of bringing treatments to market.
FAO Forum To Spotlight African AI Tools Tackling Crop And Climate Challenges
40 FAO will host the Africa Science and Innovation Forum from 27–29 October 2026 in Addis Ababa, Ethiopia, bringing toge…
$15 billion deal: Roche bets on China — and questions Germany’s future
Why it matters: Roche is expanding its collaboration with Chinese pharmaceutical company Hansoh. A year after their first agreement covering an antibody-drug conjugate (ADC) candidate, the two companies have now agreed to another, substantially broader development and licensing partnership. It covers a wide portfolio of ADC programs targeting various cancers. Hansoh could receive more than $15 billion in total development, regulatory and commercialization milestone payments, as well as sales-based royalties. In addition, it will receive a $400 million upfront payment and a further $110 million on the agreement’s first anniversary.
Merck to buy siRNA specialist Silence Therapeutics for $1.3 billion
The deal: The purchase price is $20 per American Depositary Share (ADS) in cash. This corresponds to an equity value of approximately $1.3 billion and an enterprise value of about $1.1 billion. The transaction is expected to close in the first quarter of 2027, subject to customary conditions, including approval by Silence shareholders and regulatory clearances. It is to be financed through new debt.
“Cosmetic cowboy” crackdown: England proposes beauty procedure restrictions
The UK government this week announced a new set of proposed regulations hiking guardrails against unqualified personnel from carrying out cosmetic procedures in England.
盐城利民：深耕农化行业四十载，启航百年愿景新征程
承四序耕耘，启利民新章。始创于1986年的盐城利民农化有限公司，深耕农化行业四十载，通过持续创新、砥砺笃行，现已发展成为集科研开发、原药合成、制剂加工、国际贸易、植保信息服…
Solabia sharpens cosmetics focus with diagnostics divestment
Ingredient supplier Solabia is sharpening its focus on cosmetics, nutrition, and life sciences. Astorg, Solabia’s majority owner and pan-European private equity firm, has announced it is strategically repositioning the company’s portfolio.
Amazon Prime sales reward beauty brands building demand before discounting
Beauty and Cosmetics was the most-purchased category on Amazon during Prime Big Deal Days 2026, held earlier this month from October 6–7. During the shopping event, skin care brands claimed nine of the top ten bestselling spots, but according to a report by Market Defense, prior demand drew shoppers in more than the lure of a discount.